The lawsuit does not change the company's financial expectations for the year 2000.
Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of enzymes for industrial use. Headquartered in Denmark, Novo Nordisk employs approximately 15,200 people in 68 countries and markets its products in 179 countries. Its B shares are listed on the stock exchanges in Copenhagen and London. Its ADSs are listed on the New York Stock Exchange under the symbol "NVO". A demerger of Novo Nordisk with the intention to spin off the Enzyme Business into a separately listed company is expected to take place around the turn of the year 2000/2001. For further company information, visit Novo Nordisk on the World Wide Web at www.novo.dk.
For further information please contact:
Communications & Design
Media:
Gitte Dethlefsen
Phone (Direct): (+45) 4442 1960
Gitte Dethlefsen
Phone (Direct): (+45) 4442 1960
Media in North America:
Susan Toth Jackson
Phone: (+1) 212-867-0123
Susan Toth Jackson
Phone: (+1) 212-867-0123
Investors:
Michael Steen-Knudsen
Phone (Direct): (+45) 4442 6048
Michael Steen-Knudsen
Phone (Direct): (+45) 4442 6048
Investors:
Rasmus Holm-Jørgensen
Phone (direct): (+45) 4442 2983
Rasmus Holm-Jørgensen
Phone (direct): (+45) 4442 2983
Investors in North America:
Peter Lundby Hansen
Phone: (+1) 212-878-9607
Peter Lundby Hansen
Phone: (+1) 212-878-9607